DDInter130 DDInter834
Atenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions. Sir James Black, a Scottish pharmacologist, pioneered the use of beta-blockers for the management of angina pectoris in 1958 for which he received the Nobel Prize. Beta-blockers quickly became popular in clinical use and where subsequently investigated for use in myocardial infarction, arrhythmias, and hypertension during the 1960s. Later they continued to be investigated for use in heart failure throughout the 1970-1980s. Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981.[label] Despite being one of the most widely prescribed beta blockers, evidence suggests atenolol may not significantly reduce mortality, and only modestly reduce the risk of cardiovascular disease in patients with hypertension.[A235850,A235855] A Cochrane review
Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers.[A233570,L33090] Later research, taking advantage of the systemic distribution of muscarinic receptors through the body, found that glycopyrronium could also be used for reducing sweat gland, oral, airway, and gastric secretions; as well as reducing cardiac inhibitory reflexes; and reducing bronchoconstriction in COPD. Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than [tiotropium]. Glycopyrronium was originally granted FDA approval on 11 August 1961.
Atenolol {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Glycopyrronium
Atenolol {u} (Compound) resembles {v} (Compound) Bisoprolol
Bisoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glycopyrronium
Atenolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glycopyrronium
Atenolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glycopyrronium
Atenolol {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Oxybutynin
Oxybutynin {u} (Compound) resembles {v} (Compound) Glycopyrronium
Atenolol {u} (Compound) causes {v} (Side Effect) Vision blurred
Vision blurred {u} (Side Effect) is caused by {v} (Compound) Mepenzolate
Mepenzolate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glycopyrronium
Atenolol {u} (Compound) causes {v} (Side Effect) Ventricular tachycardia
Ventricular tachycardia {u} (Side Effect) is caused by {v} (Compound) Hydrochlorothiazide
Hydrochlorothiazide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glycopyrronium
Atenolol {u} (Compound) causes {v} (Side Effect) Sweating
Sweating {u} (Side Effect) is caused by {v} (Compound) Phenelzine
Phenelzine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glycopyrronium
Atenolol {u} (Compound) resembles {v} (Compound) Bisoprolol
Bisoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Mepenzolate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glycopyrronium
Atenolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Mepenzolate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glycopyrronium
Atenolol (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Glycopyrronium (Compound)
Atenolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Atenolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Atenolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Atenolol (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Oxybutynin (Compound) and Oxybutynin (Compound) resembles Glycopyrronium (Compound)
Atenolol (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Mepenzolate (Compound) and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Atenolol (Compound) causes Ventricular tachycardia (Side Effect) and Ventricular tachycardia (Side Effect) is caused by Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a minor interaction that can limit clinical effects when taken with Glycopyrronium
Atenolol (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Phenelzine (Compound) and Phenelzine may cause a minor interaction that can limit clinical effects when taken with Glycopyrronium
Atenolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Atenolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium